Overview

A Dose-Ranging Study of the Efficacy of ABT-894 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
A Dose-Ranging Study of the Efficacy of ABT-894 in Adults with Attention-Deficit/Hyperactivity Disorder (ADHD)
Phase:
Phase 2
Details
Lead Sponsor:
Abbott
Treatments:
Atomoxetine Hydrochloride